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INTRODUCTION:  Welcome to "Healing 
Appalachia, The Role of Professionals in Solving the 
Opioid Crisis."  My name is Michael Deel.  On behalf of 
the Tennessee Journal of Law and Policy and the 
University of Tennessee College of Law, thank you for 
attending.   
Today we have gathered experts who are working 
to find legal and political solutions to this public health 
crisis while also working with individuals who are 
suffering on a day-to-day basis. I invite you to not only 
listen to their stories but to learn from them and to 
remember their efforts when you make your own 
everyday decisions, decisions like how to help a friend, 
how to effect policy, how to find hidden information, or 
simply how to vote in the next election.  
I would like to thank all the panelists and 
moderators that are participating today and also thank 
everyone who helped put this event together.  So many 
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people gave their time and energy to make this 
symposium possible.   
Mr. Eric Eyre and Professor Patrick McGinley will 
deliver our keynote address which will be followed by two 
panel discussions and a documentary viewing.  We will 
take a 15-minute break between each session and there 
will be a transcript available after we get it published in 
the next issue of TJLP.  
Mr. Eyre won the Pulitzer Prize for investigative 
reporting for his articles regarding the distribution of 750 
million prescription pills in West Virginia and the tragic 
overdoses that followed those pills.  He currently works 
as a statehouse reporter for the Charleston Gazzette-
Mail. 
Professor McGinley is a Charles H. Hayden II 
Professor of Law at West Virginia College of Law. 
Professor McGinley teaches administrative law, 
environmental law, and appellate advocacy.  He also 
represented the Charleston Gazzette-Mail in a lawsuit 
that resulted in a court order unsealing the documents 
that led to Mr. Eyre's articles.   
Professor Becky Jacobs from the University of 
Tennessee College of Law will moderate this discussion. 
Please join me in welcoming them. 
 
MS. JACOBS:    So just to like frame our 
discussion this afternoon, I want to give you just a few 
facts.  So opioid painkillers are a nine-billion-dollar-a-
year market in the U.S. alone.  In pharmaceutical 
companies such as Purdue Pharma, Johnson & Johnson, 
Teva, and Allergan have all earned many billions over 
the years from the sale of these drugs.  Wholesaler 
distributors like McKesson, Cardinal Health, and 
AmerisourceBergen also have profited, as have the 
physicians and pain clinics that prescribe these 
medications, some legitimately, some not so legitimately.   
These profits, though, have had a very, very high 
public health cost as the work of our guests today helped 
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to expose.  According to the CDC, from 1999 to 2016, more 
than 200,000 people have died in the U.S. from overdoses 
related to prescription opioids.  That's just the 
prescription opioids.  In 2016 alone, more than 46 people 
every day have died from overdoses involving 
prescription opioids.  Also in 2016, three of the five states 
with the highest rates of death due to drug overdoses 
were close to us:  West Virginia had 52 per 100,000, Ohio 
had 39.1 per 100,000, and Kentucky had 33.5.  
Tennessee's rate was 24.5.  And our guests today fought 
to make these data public. So I want to thank them very 
much for being here. 
I want to start by asking you, for those who aren't 
familiar with kind of what these drugs are, can you 
describe the specific painkillers that we're talking about 
and which ones are the focus of this investigation? 
 
MR. EYRE:      Sure.  The two that we primarily 
focused on, because we got the DEA data on were 
hydrocodone, which is Lortab and Vicodin, and 
oxycodone, which is OxyContin.  And there's plenty of 
other pills that are distributed, but those were the two 
that we focused on primarily. 
 
MS. JACOBS:    Okay.  So how you did you get 
interested in the topic, and how and when did Pat get 
involved? 
 
MR. EYRE:      I kind of wound up in it in a 
different way.  I covered the legislature for West Virginia, 
so I'm based at the Capitol, and we had a new attorney 
general elected in our state.  There had been a lawsuit 
filed about six months prior to his win by our former 
attorney general, and that lawsuit was against the drug 
wholesalers.  When our new attorney general got elected, 
I got this phone call that this woman wanted to meet with 
me outside the Capitol; she had some information for me.   
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She brought this envelope of stuff.  She had— I 
remember it was crazy because she had a dog with her 
named Bernard the Pekinese.  So she's literally handing 
stuff out and I'm worried I'm going to get bit by this dog, 
Bernard the Pekinese.  What it was was information 
about the new incoming attorney general's ties to these 
drug wholesalers.  The one company that you mentioned, 
Cardinal Health, had paid for his inauguration, and then 
when we also looked back at contributions, a lot of these 
drug wholesalers after the lawsuit was filed in July of 
2012 had given money to the attorney general.  And so 
we did a story about that and he said over and over that 
he had recused himself from the case at the beginning of 
when we assume he took office, but we had heard from 
staff that that wasn't the case.  So we actually filed a 
number of Freedom of Information Act requests and that 
wound up in court.   
This photo here is— the attorney general is on the 
right there.  This was a photo taken by a New York Times 
reporter, Eric Lipton, who actually won the Pulitzer Prize 
two or three years ago and he was writing about both the 
Republican Attorneys General Association and the 
Democratic Attorneys General Association wining and 
dining various attorneys general to get them— to try to 
persuade them to drop lawsuits or not file lawsuits.  And 
the woman there is Pam Bondi. I believe she's still the 
attorney general in Florida. 
And the story was about her being pushed— this 
was in the Hotel del Coronado in San Diego, a beautiful 
resort there— she was being pushed to drop a lawsuit 
against 5-hour ENERGY.  And these guys are lobbyists.  
I think it was something like three thousand dollars a 
night to stay there.  I met the reporter at the Pulitzer 
ceremony.  And eventually when they found out what he 
was doing, he got kicked out of course but . . .  So the next 
step was the FOIA lawsuit, and maybe Pat can talk a 
little bit about that.  This is back in 2013, 2014. 
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MR. MCGINLEY:  Yeah.  So— 
 
MS. JACOBS:    Before you do that, step back a 
little bit and— 
 
MR. EYRE:      The lawsuit— 
 
MS. JACOBS:    —the first lawsuit that Darrell 
McGraw filed. 
 
MR. MCGINLEY:  So in was it 2012 a long-time 
West Virginia attorney general, Darrell McGraw, filed 
the first case against drug distributors of opioid drugs, 
recognizing the impact of opioids in West Virginia, and, 
really, the first public official to take some kind of action.  
The lawsuit, the cause of action, was new and it was 
suggested that this is a looser, the attorney general's 
office is up against Big Pharma, billion-dollar 
enterprises, lawyers from New York and Philadelphia 
and Cleveland.  But that lawsuit was filed.  And then in 
a very narrow election, Attorney General McGraw lost to 
Patrick Morrisey.  He's pictured there in blue jeans with 
a lobbyist and the attorney general of Florida.  And so 
within six months of the time that these "pill mill" cases, 
that's what they were referred to, were filed in the 
summer of 2012, a new attorney general who had 
formerly been a lobbyist for trade associations from the 
pharmaceutical industry took office. 
 
MR. EYRE:      And what I forgot to mention, his 
wife was the lead lobbyist for Cardinal Health in 
Washington D.C. and made millions of dollars. 
 
MR. MCGINLEY:  Cardinal Health being one of 
the three leading opioid drug distributors in the country.  
And she continued to be a lobbyist until after our lawsuit.  
There was an ethics complaint filed against the attorney 
general at some point and said, well, I don't have to do 
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this but I won't have my fingers on any of these cases.  
But that took a couple of years.  In the meantime, Eric 
and the Gazzette-Mail are interested in what this new 
attorney general was going to do in terms of supervising 
these "pill mill" cases, considering his former relationship 
with the industry.  And Eric filed several FOIA requests 
and he was basically stonewalled, the responses didn't 
meet the requirements of the West Virginia Freedom of 
Information Act.  I think the first one, they said, well, if 
we had these documents you're requesting that relate to 
whether the attorney general is supervising the "pill mill" 
cases, if we have them, they would be exempt.   
And, you know, at that point the Gazzette asked 
me to be of assistance, because I've done a lot of FOIA 
stuff, and so I wrote to the attorney general and I said, 
well, that's not good enough, you've got to look for it, you 
can't just say if you have it.  And then there was a series 
of back and forth with nonresponsive answers from the 
attorney general, and I would say, well, let's read the law, 
you know, you must have something.  And then, 
ultimately, after about six months, they said— they 
called Eric and said, okay, you can come and look at the 
documents but they are totally redacted and you can't 
take photographs, and they set a time for it.  And we 
talked and we responded, that's not what the law 
requires, no, we're not doing that.  And they said, we'll 
get back to you.   
They didn't get back to us.  We filed a FOIA suit.  
It went on for almost a year.  We did discovery.  We found 
out they had documents that they hadn't mentioned 
before but they claimed were attorney-client privilege, 
work product.  And we thought we had a really good 
paper trail, a good case for joint motions for summary 
judgment, cross motions for summary judgment.  And the 
judge ruled against us and granted summary judgment.  
And I was depressed.  I thought this is a winner.  Eric 
and the others at the Gazzette were taken aback.  And 
then something happened that was interesting. 
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MR. EYRE:  So after we lost the FOIA case, 
somebody— I was not home.  This is a recreated— 
actually I found this— this is actually the envelope that 
it came in but somebody walked up to our house and my 
son texted me at work and said some man just came up 
to our house and dropped something in the mailbox with 
your name on it. 
Go to the next slide. You can't see it there but that 
was one of the e-mails that was being withheld, and what 
it said in the e-mail was that the attorney general has 
specific instructions regarding this case.  So it was hard 
to believe— he had done multiple interviews, not just 
with me but with other media, over and over again saying 
that he was completely recused from the case, he had had 
nothing to do with it since the day he took office.  And 
this countered his assertions for sure.  And then where 
do you want— 
 
MR. MCGINLEY:  Well, so Eric wanted to write 
about this of course— 
 
MR. EYRE:      Oh yeah. 
 
MR. MCGINLEY: —because this is exactly the 
opposite of what the attorney general had stated in court 
proceedings. And so, Eric, you can tell the story.  As 
reporters usually would do, you asked him for comment. 
 
MR. EYRE:      Yeah.  They required all their 
questions to be e-mailed, so I e-mailed a bunch of 
questions about when you said that you recused yourself 
from the case, it would seem this contradicts what you 
are saying.  We also found at around the same time there 
had been some documents saying that a court hearing 
related to this drug distributors lawsuit had to be 
canceled because Attorney General Pat Morrisey can't fit 
it into his schedule and can't make it.  And so if he was 
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recused from the case, why would they be saying he 
couldn't be there and things like that.  So I e-mailed to 
their press person these questions about what's going on. 
And then the next thing you know, their general counsel 
called or e-mailed you, Pat.  
 
MR. MCGINLEY:  Their solicitor general. 
 
MR. EYRE:      Became solicitor general. 
 
MR. MCGINLEY:  We never had a solicitor 
general in West Virginia but it sounds like a good title.  
Yeah, he called me, and I was actually here in Knoxville, 
at the time I was on my way to the Public Interest 
Environmental Law Conference, and I get the call on my 
cell phone from Misha— 
 
MR. EYRE:      Misha Tseytlin. 
 
MR. MCGINLEY:  —Tseytlin. 
 
MR. EYRE:  He's now the solicitor general at 
Wisconsin. 
 
MR. MCGINLEY:  —and there were documents 
that were in the files of the court in our FOIA case that 
were produced by (inaudible) and that were examined by 
the court, quashed by the court in camera before it 
granted summary judgment against us.  And so he called 
me and he said you better tell your client not to publish 
this story about documents that are under seal in the 
court, you're going to be sanctioned, and we're not going 
to tolerate this. And, you know, I'm in the rental car 
and— 
 
MR. EYRE:      And I'm like am I going to jail or . 
. . 
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MR. MCGINLEY:  And I said, Misha, have you 
ever heard of the Pentagon Papers case?  Misha was a 
law clerk to Justice Kennedy, so he knew the story. I said 
you do what you want but I can assure you this is going 
to go to print.  But that wasn't the end of the story.  We 
had to have conversations with the editor and publisher 
and they were concerned with are they going to sue us.  
And I said they can sue you, anybody can sue you, but 
this is a winner.   
And they went ahead and Eric told the story.  It 
didn't have much impact.  He continued to deny and it 
just sort of went over people's heads.  But we knew about 
that, it was clear the relationship there.  The overarching 
concern was that the attorney general would somehow 
dump the "pill mill" cases, that it would settle them cheap 
or make errors, who knew, who knows.  But he certainly 
with the appearance of impropriety with his prior 
relationships and the representations made to the Court, 
he shouldn't have been involved at all. 
 
MS. JACOBS:    Well, in fact, he wasn't very 
aggressive about the data that you guys had to intervene 
to get.  So tell us about that.  Because that's what broke— 
 
MR. EYRE:      That was— that was the next thing.  
So if we sort of flash forward, I kind of kept following the 
story and started seeing stuff in various legal filings.  But 
in I think it was around March 2016 we got wind that 
there had been what was called a second amended 
complaint or a revised complaint.  When they filed the 
original lawsuit back in 2012, the judge in this rural 
county that was handling it said we need some specifics 
here, we need some examples of, you know, this sending 
these larger quantities of drugs, these "pill mill" 
pharmacies. So they had filed an updated complaint 
called the second amended complaint and it was filed 
under seal. So this was the State of West Virginia filing 
a complaint outlining its allegations against the drug 
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distributors and you couldn't see it.  It was just 
completely filed under seal.  And I went to Pat and said, 
is this possible. 
                 
MR. MCGINLEY:  Yeah.  I said, well, that 
certainly violates the West Virginia Constitution, 
violates West Virginia Freedom of Information Act, and 
the West Virginia Rules of Civil Procedure. So the 
general rule is that public documents should be public 
when they are filed with the court.  And here he had a 
complaint on behalf of the State that says on behalf of the 
people of West Virginia against these drug companies, 
but the people don't know what the allegations are.  And 
so the State itself had come around to the point where it 
wanted the second amended complaint to be unsealed, 
but the Court did nothing and they didn't assert that 
aggressively.  So I talked to Eric, and I got other things 
to do at the law school, and I'm thinking well they are 
going to act, nothing happened, so we filed a motion to 
intervene for the purposes of seeking unsealing of the 
second amended complaint, which is in the materials that 
you have.  And we basically argued that there's no law on 
the side of the drug companies.   
Their response, which I think is in the material as 
well, was that these are essentially trade secrets, 
confidential business information about how many pills, 
opioids, that we sell to pharmacies, so our competitors 
would find out who the pharmacies are and how much.  
And, you know, we read that and said, what?  And not 
only that, it was old data.  And we went to Boone County 
Circuit Court for a hearing.  There were lawyers from 
everywhere.  The court was filled. 
 
MR. EYRE:      It's a picture from the courtroom. 
 
MR. MCGINLEY:  That's our co-counsel from 
Boone County, Tim Conaway.  And we were totally 
outnumbered.  There must have been 40 lawyers there 
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for the various drug companies and pharmacies. And we 
argued the case. And the judge eventually said he was 
going to rule to unseal the documents, and then one of 
the drug companies filed a motion and wanted to have a 
conference call and— what did they say— 
 
MR. EYRE: There was like this 11th hour try to 
block the release of this— to unseal this complaint and 
what they said was they wanted to redact 18 words. We 
had a conference call about it, and I think they filed 
something too. And they said— and it was probably 70 
pages long. And they said we just want to redact 18 
words. They just kept saying if you can keep these 18 
words out, we're good with that. Well, it turned out— I'm 
making a spoiler alert here, I'm jumping ahead— but it 
turned out the 18 words were 18 numbers and it was 
numbers of pain pills. They said words. 
 
MR. MCGINLEY: Yeah. And, well, the judge 
didn't buy that. He ordered the complaint to be unsealed. 
And then that gave Eric insight into the bigger story, the 
sheer volume of opioids that were being marketed in the 
places they were being marketed. When we saw that first 
information, we were stunned. We're talking about a 
couple hundred million doses over a five-, six-year period. 
But there was more. But Eric wrote a story that was part 
of the Pulitzer recognition in May of 2016. You can 
describe what— 
 
MR. EYRE: That one was some of these numbers 
were— these orders were shipped— you have 20,000 
oxycodone to one pharmacy in a little town of a couple 
hundred people, and then it would say on the following 
week they'd get another 50,000, and then the next week 
they'd get another 20,000. So it was just these large 
shipments over consecutive days or consecutive weeks. 
And what the average hydrocodone I think nationally is 
90,000 per pharmacy per year, and oxycodone is probably 
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like 50,000 doses per year. So these small-town 
pharmacies were getting the equivalent of what they 
should have gotten in a year in a matter of a week or two. 
But what ultimately happened though, where this really 
opened things up, is throughout the complaint that was 
unsealed, they kept referring to DEA data shows, DEA 
data shows, DEA data shows this, that, and the other. So 
I did a FOIA asking the attorney general's office for all 
the DEA data that they used to cite all these various 
figures. And it turns out that there was a 2015 e-mail 
sent from DEA to the attorney general's office outlining 
every shipment to every pharmacy in West Virginia of 
hydrocodone and oxycodone and also it was broken down 
by the name of the company and how many pills they 
distributed to each county in West Virginia. And what 
we— just to sum it up, after we got this DEA data, there 
was a disproportionate number of pills sent to the 
southern part of the state, the coalfield region.  
And you had these situations where you had 
pharmacies with— one town had a pharmacy— 400 
people— and got nearly nine million hydrocodone pills in 
two years, in just two years. There were cases like this all 
over southern West Virginia, Logan County, Boone 
County, Mingo County. They had a town of 3,000 in 
Mingo County, they got 20 million hydrocodone over 
eight years. Just these incredible numbers. And then we 
looked at, you know, we did the (unintelligible) maps and 
looked at where most of the overdose deaths were, and 
they don't line up perfectly, but they match up pretty 
closely. And these counties here, not only are they 
number one for prescription drug overdose deaths in 
West Virginia, but they are I think of the top 10 about six 
or seven of them were all in West Virginia in the country 
for overdose death rates. So it was an incredible thing. 
And, in addition, I don't have a slide to show it, but the 
DEA agent who sent the data to the attorney general's 
office, he also did a— he mapped out the strength of the 
pills of the OxyContin, the milligram levels had 
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increased. So you had in 2007 the most popular milligram 
level of OxyContin was five milligrams, and then the next 
year it was like 10 milligrams. So the strength of the pills 
were actually getting stronger too in terms of— 
 
MR. MCGINLEY: How high did they go? 
 
MR. EYRE: They had OxyContin 80, but that was 
outlawed I believe. 
 
MR. MCGINLEY: But they went beyond 10, it 
went pretty far above it. 
 
MR. EYRE: Yeah, I think it went to like 30. 
 
MS. JACOBS: I know there's a quote from your 
article that there were 433 pain pills for every man, 
woman, and child in West Virginia. 
 
MR. EYRE: Just those two, right. I mean, we're 
not even doing hydromorphone, oxymorphone, Xanax, 
and all the others. 
 
MS. JACOBS: That's astounding. 
 
MR. MCGINLEY: There's one parenthetical that 
Eric was— when he filed actually a Freedom of 
Information Act request with the attorney general 
seeking the DEA data in August of 2016. And under West 
Virginia law, a FOIA law response is required within five 
working days. Well, the attorney general's office kept 
delaying, we're looking for the data, we'll get back to you, 
we'll get back to you. Meantime, there's an election going 
on where the attorney general is running for re-election. 
His opponent has a lot of cash and is running— has spent 
several million dollars on TV ads trumpeting the 
relationship of the attorney general to the drug 
companies and the opioid epidemic. And there was an 
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infusion of cash into Morrisey's campaign in October of—
what was it— six million dollars from the National— the 
Republican Attorneys General Association, more money 
that flowed from that association than any other attorney 
general race. That money is sort of dark money. The 
contributors are the Koch brothers, pharmaceutical 
companies. And so the attorney general continued to 
delay responding. And what happened then? 
 
MR. EYRE: Pat came up with a good idea that we 
should file a FOIA asking them— because they kept 
responding that they are searching for the records, they 
are searching for the records, and they would just keep 
every five days saying we're still searching for the 
records— Pat came up with an idea just to do a FOIA 
saying any documents that would show you're actually 
searching for the records. Of course there were none. And 
then about two or three weeks before the election he did, 
to his credit, he did release the DEA data.  
The backdrop, as Pat was describing, was this 
immense pressure in terms of ads from the democratic 
opponent. Actually, CBS News had picked up on our story 
and came to West Virginia multiple times. And the 
attorney general agreed to do an interview with CBS 
News, which I can't— I don't know who told him to do 
that. But of course they did the things where they are 
asking all these happy questions and then they say what 
about your wife works for Cardinal Health and you have 
this lawsuit and, you know, they zero in on your face and 
you start seeing the twitches and all that. Well, the 
democratic guy that was running against him just kept 
running that interview over and over in his ad. But that 
was countered by all the money from the Republican 
Attorneys General Association who said that the 
democratic opponent was big friends with Hillary Clinton 
and Obama and they pounded that over and over and 
over, which is a simple effective message that worked. 
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MR. MCGINLEY: And Attorney General Morrisey 
won the election. It was close but he prevailed. I don't 
know that I would give him credit because he knew that 
Eric and the Gazzette were going to write stories and we 
were considering a lawsuit against him, a FOIA suit, that 
would have come out right before the election. So I think 
he had some good political counselors in-house that said 
you better get this information out there. And it's really 
a question whether that information should be— should 
not be available to the public because it came from the 
DEA. And that's more the problem, all this information 
the DEA has but it's not shared, the public doesn't have 
access to it. So the public knows because of Eric's 
reporting the volume of prescription opioids that were 
sold in West Virginia. But we don't know, we don't have 
the data at this point, about the sales in Ohio, in New 
Jersey, Tennessee, Kentucky, and so forth. And that's a 
real flaw in the system. But subsequent to Eric's 
reporting there have been numerous lawsuits that have 
been filed here in Tennessee, for example, by 
Municipalities, Indian tribes, Cities, States, against the 
drug manufacturers and distributors seeking 
compensation for the cost of dealing with the opioid 
epidemic, which is enormous.  
The American Enterprise Institute report just 
came out pegging the cost to the gross domestic product 
in West Virginia of eight billion dollars. That sounds high 
to me but I don't know. And the human cost, you can't 
calculate that. And, hopefully, in these cases that are, you 
know, following up on what West Virginia did, that 
litigation and exposure. But the volume— I was looking 
at the audience here, we were talking about how many 
oxycodone, OxyContin pills, and the total is 780 million. 
And when we saw that, I said oh my God. I think that's 
what a jury would do, if you've got a case where you could 
get it to the jury. It's a question of creative lawyering, 
having statute or common law remedies that will make 
these— hold these billion-dollar companies responsible. 
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And that's one of the grossest things about this whole 
story is the billions of dollars that these companies have 
made and there have been very few repercussions, 
certainly not to the companies. Three of the top 15 
Fortune 500 companies are drug distributors and were 
parties in the "pill mill" litigation in West Virginia. 
McKesson, Cardinal Health, Amerisource Bergen, not 
household names, but they're right up there with Wal-
Mart and Apple. And what do they do? I mean, what— 
 
MR. EYRE: They ship drugs from factories to 
warehouses to pharmacies and hospitals. 
 
MS. JACOBS: Purdue Pharma who produces 
OxyContin— 
 
MR. MCGINLEY: The manufacturer. 
 
MS. JACOBS: —they're the manufacturer, 
privately owned by a family, and they are I think the 
wealthiest, or maybe behind Bill Gates, in the country. 
 
MR. EYRE: Well, like McKesson is the number 
five on the Fortune 500. And that shocked me. I didn't 
even figure that all out until we were in the courtroom 
and I turned around and introduced myself, and 
somebody was telling me they were from D.C. and like 
Cardinal Health or the other companies would have three 
or four lawyers there. We don't have the rankings but I 
think it's Wal-Mart, Apple is number two on the Fortune 
500, or Berkshire Hathaway, Exxon, and then McKesson 
is number five. And then I'm not going to get these 
exactly right but I think AmerisourceBergen is 12 and 
Cardinal Health is 15. And they've actually climbed— 
since my story has come out, they've actually climbed in 
places in the Fortune 500. These are CEOs that are 
making— a guy in McKesson— there's been stories in 
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Fortune or Forbes— Forbes— making over 60 million 
dollars a year in compensation. 
 
MR. MCGINLEY: The McKesson CEO one year 
was the highest paid CEO of any corporation in the 
United States. 
 
MR. EYRE: And nobody had heard anything. 
 
MS. JACOBS: I've heard another topic you've 
done. You were talking about the distribution 
outlets, some of the pharmacies. It wasn't Wal-Mart or 
Walgreens or— tell us about where these pills were being 
distributed in West Virginia. 
 
MR. EYRE: Yeah. That was surprising. Because 
before I covered the— as you guys know a lot about the 
meth epidemic when they're doing the shake and bake 
bottles and making it with Sudafed, and we used to 
identify the pharmacies that were selling the most 
Sudafed in the state and they were typically the Wal-
Marts and the Rite Aids. But in this case it was these 
independent pharmacies, these mom and pop 
pharmacies. They were literally drive-thru pharmacies. 
They didn't sell Band-Aids, they didn't sell Q-tips. They 
literally had names like Meds To Go Express and Larry's 
Drive-thru Pharmacy. And you'd see people lined up up 
and down the block. People would come from all over. You 
know, I've seen recent stories where some of these 
pharmacies are defending themselves saying we just 
didn't serve the town of 400, people came from all over. 
But I think that's more damning than— I mean, they 
were literally coming from Tennessee, Kentucky, Ohio, 
Pennsylvania to these little small towns in the southern 
part of West Virginia. Whitfield, Virginia is another 
place.  
And you had these— you know, I wasn't there— 
but everybody describes these scenes that there's one 
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pharmacy in Kermit, which is this little town of 400 
people, because there were so many people in line, they 
started handing out bags of free popcorn just as a bonus. 
They had bags for the people in town where if it was 
opioids, you'd get it in one color bag, and if not, like if it 
was blood pressure medication, you'd get it in another 
color bag, because they didn't want the senior citizens in 
town getting robbed. Because if the people would see you 
had the color bag that wasn't opioids, then they wouldn't 
rob you. They actually set up a hotdog stand with 
hamburgers and hotdogs while people were waiting in 
line. It was just an unbelievable scene from what's been 
described to me. 
 
MR. MCGINLEY: What about the doctors? I refer 
to this as a legal cartel. You have the Mexican brown 
heroin cartel or Columbian cocaine cartel. You have the 
legal cartel, you've got manufacturers, you've got the 
distributors, you've got the doctors who were writing the 
scripts, you've got the pharmacies who were filling the 
prescriptions, they all had to know. With those numbers, 
all of them knew. And where was the law enforcement? 
Where is the Pharmacy Board? Where was the DEA? And 
this was going on for more than a decade. And I think the 
numbers, when we finally saw the numbers, the light 
went on and the country woke up to realize that this was 
all legal and they had— the defense was of the 
manufacturers, well, we're just making stuff to help 
people with their pain. The distributors, we're just taking 
them to the pharmacies. The pharmacies, we're just 
filling the doctors' prescriptions. And the doctors saying 
we're helping our patients with pain. They are all 
pointing fingers, they didn't do anything wrong. The 
doctor's office, what was that like? 
 
MR. EYRE: Just last week or this week they 
busted what's called The Hope Clinic. I think at one point 
they had— yeah, what a name for a "pill mill" pain clinic, 
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The Hope Clinic, we're giving people hope— I had 
actually written about them. One of the prisms of my 
stories is they only focused on the drug wholesalers. My 
mom called me the day that story came out, when it first 
came out back in December 2016, she said what about the 
doctors. And I said I've been writing about the doctors for 
years. They had these pain clinics where the doctors 
didn't even show up. The one that just got busted that we 
wrote about back in 2014, 2015, they had former cops, 
retired cops, who were taking people's blood pressure, 
doing the weight, doing their charts. They carried guns 
holstered at the site. They had these special machines, I 
can't remember the exact name of them, but they were 
these electronic machines that would crank out 
prescriptions by the hundreds. They would have the 
doctor’s signature on them, but they were just being 
reproduced through the machines. And I would get calls 
back in 2014, 2015 from legitimate pharmacists that 
would call me up and say come up and let me show you 
what they are doing, you know. But they would set up 
special relationships with some pharmacies that were 
disreputable, and they would fill those prescriptions. And 
it was an all cash basis. There was no insurance or 
anything like that. It was just a cash only business. 
 
MS. JACOBS: It's astounding that— where was 
the Board of Pharmacy? In your third article you talked 
about the responsibility to file reports about large 
shipments. What happened with all of that? 
 
MR. EYRE: Well, our Board of Pharmacy is 
almost exclusively made up of independent mom and pop, 
including some that were involved in this "pill mill" stuff. 
Their directors are all appointed by the governor and 
they are all independent pharmacists. So they had some 
rules on the books related to something called "suspicious 
orders" and those are orders of large numbers of drugs 
over consecutive days or massive quantities over one day. 
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MR. MCGINLEY: Those are Federal rules; right? 
 
MR. EYRE: It was a DEA rule that the State had 
copied and put into their rules at the Board of Pharmacy. 
And I asked our executive director of our Pharmacy 
Board, because it was cited in the lawsuit, I said what are 
you doing with that. They said that hasn't been on my 
radar, we just don't enforce that rule. So there had been 
no suspicious order reports filed by any of these drug 
wholesalers before 2012. But when the lawsuit was filed 
by the former attorney general, a couple of them— two of 
them started sending suspicious order reports to the 
Board of Pharmacy, sometimes two or three a day. I went 
and said can I take a look at them. I thought they would 
be cataloged, they'd have a total number or something. 
And they just came— I came into the office and they came 
in with two big bankers boxes full and they dropped them 
on the table and they said here is all our suspicious order 
reports. And I said, well, what have you done with them. 
And they said we haven't done anything with them, we 
just shelve them. And they hadn't cataloged them, so I 
literally had to count through each one to figure out how 
many had been filed. 
 
MS. JACOBS: Were they included in the lawsuit, 
the warrant? 
 
MR. MCGINLEY: Not at that point, no. 
 
MS. JACOBS: That's amazing. So talk a little bit 
about the consequences, like the kind of after-effect. Your 
work had a significant impact on all the lawsuits that 
happened. And what else do you think you have done, 
your work has done? 
 
MR. EYRE: Well, the biggest development is there 
is a congressional investigation in the House Energy and 
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Commerce Committee and what they're doing that we 
hadn't been able to do for the most part is linking up exact 
numbers from each company to each of these pharmacies, 
and many of them were shuttered, a lot of them are still 
open actually, and they've been able to sort of dovetail or 
expand upon our work. They were originally stonewalled 
by the DEA. I think in some respects the Congressional 
Committees were still being stonewalled. But they've 
come out with some more shocking numbers like 
McKesson over a two-year period they figured out of 
those nine million pills like five million were from 
McKesson alone, 76 percent of the business. They've 
gotten some real granular detail. And they've identified 
other regional wholesalers. Another name is Miami-
Luken, H.D. Smith. They're starting to get more 
numbers. But what's frustrating is, we talked a little bit 
about this earlier, the DEA, they have all this data. I get 
calls from all over the country saying can we replicate 
what you did. And I said the DEA in a matter of I can't 
imagine it would take more than an hour to do the 
spreadsheets that we got, it's a simple sort, but they just 
won't do it. They point to there's data available on their 
Web site called ARCOS data but it's broken down by 
grams and by zip code prefixes. Which I tried to look up 
our zip code prefixes in West Virginia and they span 
sometimes four or five counties or they dig into half of a 
county, and it's very complicated to do it that way. There 
are ways to see the overall number of grams by state, 
things like that, but nothing like what we got. 
 
MS. JACOBS: Yeah. So what do— I mean, I've 
noticed— 
 
MR. MCGINLEY: Can I add something there? 
 
MR. EYRE: Yeah. 
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MR. MCGINLEY: With regard to the DEA, some 
of you may have saw the story, the DEA had an official 
that was in charge of checking on the drug distributors, 
you know, for suspicious orders and volumes and was 
trying to organize enforcement actions, at least the story 
that's been told publicly, and wasn't permitted to go 
forward. I think there was pressure from higher up in the 
agency or political pressure in the regional offices. But 
there were people in the DEA enforcement that wanted 
to do something about the enormous volume of opioids 
that were being distributed. And the trade associations 
for the pharmaceutical industry hired a former member 
of the DEA's general counsel's office to draft legislation 
that essentially took away the DEA's enforcement power. 
That's the old revolving door. You know, anybody that's 
been around government knows about that. And that bill 
was written in language that was not penetrable by those 
who don't really understand the legal terminology and 
what the DEA does, and so it was sponsored by a 
congressman from northeast Pennsylvania and it was 
passed on a voice vote in both the House and the Senate 
unanimously. I think the attorney general did raise some 
question about it. President Obama signed it and 
nobody— clearly, no one read it and knew what was in 
there. So here is an effort funded by the industry to talk 
about DEA oversight and enforcement power and it just 
goes totally under the radar until the Washington Post— 
was it— 
 
MS. JACOBS: 60 Minutes. 
 
MR. MCGINLEY: —60 Minutes last fall did this 
exposé. At that time the congressman of Pennsylvania 
had been nominated by President Trump to be the new 
head of the DEA. 
 
MS. JACOBS: Yeah, the drug czar. 
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MR. EYRE: The drug czar. 
 
MR. MCGINLEY: Drug czar. 
 
MS. JACOBS: It's very interesting. It's very 
Orwellian. The name of the legislation was "Ensuring 
Patient Access and Effective Drug Enforcement Act". 
That was the name of the legislation. It sounds really 
great, so if you didn't read it, you would vote for it 
thinking this is great for enforcement. But it basically— 
the DEA, to take any kind of enforcement action, they 
have to show a substantial likelihood of an immediate 
threat. Immediate. So it's a higher bar than they ever 
had. And they also cannot sanction any company unless 
they allow them first to put in place a corrective action 
plan. 
 
MR. MCGINLEY: Which did not exist in the prior 
legislative plan. 
 
MS. JACOBS: Yeah. So it's a very different 
enforcement regime than they had previously. 
 
MR. MCGINLEY: A little bit of good news is the 
congressman's nomination was withdrawn a few days 
after the 60 Minutes show ran. 
 
MS. JACOBS: Well, apparently, there's a lot of 
outrage about it in the House and Senate, so I think 
there's a move to repeal it. So, hopefully, that might 
happen. I think there's a lot on the legal side, and 
hopefully the next panel will talk about some of the legal 
fallout from this, but I think there are over 250 public 
lawsuits, you know, Cities, Counties, and State attorneys 
general. I think every state either has a lawsuit pending 
or they are investigating lawsuits against the opioid 
industry, some faction of it. And they consolidated a lot 
of those in this multi-district lawsuit in Ohio and— but 
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the companies have tried to like get settlement 
discussions going and to seal a lot of the data that's been 
coming out of that. Interesting development I read about 
yesterday, there's some lawsuits in Michigan on RICO, 
which I think is a really great kind of cause of action, a 
really creative theory. Hospitals have begun to sue, 
which is another really interesting— looks like if the 
cities can do it, we should be able to do it. Insurance 
companies are probably next. And legislatively, I think 
people have started— I don't know if it's happened in 
West Virginia— they a resetting prescribing limits, 
which I think should have been— 
 
MR. EYRE: We have a bill pending that was just 
approved by the Senate that's been turned over to the 
House for seven-day. Do you guys have three-day or— 
 
MS. JACOBS: I don't know what Tennessee is, if 
we have one. 
 
MR. EYRE: Some states have three-day, some 
have five-day limits. 
 
MS. JACOBS: And there are other— and just last 
week I think, the OxyContin manufacturer, Purdue 
Pharma, said they are not going to market to doctors 
anymore. I'm not sure at this point that makes any 
difference since they're firmly entrenched but . . . 
 
MR. MCGINLEY: Marketing to doctors often 
means paying doctors large amounts to give a talk at 
some proceeding sometimes in Rome or Paris or resorts, 
and it can be very lucrative for doctors and inroads to 
doctors prescribing particular drugs. It's not only in the 
opioid field but certainly makes a difference. Purdue 
Pharma has one of the worst records in terms of they're 
really marketing their opioids as not being addictive. 
That was the first round. I mean, that's when the opioids 
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really started to kick off, you know, doctors prescribing 
them, manufacturers saying they are not addictive. Am I 
right about that? 
 
MR. EYRE: Yeah, absolutely right. 
 
MS. JACOBS: They said it was something like 
ibuprofen. 
 
MR. EYRE: Our public health commissioner is one 
of the champions at trying to reduce that the opioid 
epidemic— he's really a good guy. He's like— he actually 
came from Tennessee and he's like, you know, we just 
were fed a bill of goods, and he's regressed and he's like I 
was a big prescriber of OxyContin. When I talk about 
these "pill mills", I mean, these were guys that had been 
like disciplined in other states, that lost their license in 
other states, and then show up in southern West 
Virginia. These were bad, bad guys. 
 
MR. MCGINLEY: Can I say just one thing about 
that? 
 
MR. EYRE: Yeah. 
 
MR. MCGINLEY: The legal actions now that have 
multiplied, I mean, they are looking for reliable legal 
theory, might be RICO, might be common law, whatever, 
but the thing that exists is intent and knowledge. You 
can't look at those numbers and believe that this was a 
legal operation. And the doctors made millions. The 
pharmacies made millions. The distributors and the 
manufacturers made billions. So, you know, there's the 
intent, there's the knowledge. It's looking for creative 
lawyers and law that would at least try to bring some 
money back to the communities and try to figure out what 
the solutions are. And I know you're going to be talking 
about that on panels this afternoon. I mean, this is a long 
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road. It's difficult. Money is important and it's just one of 
the parts of the puzzle. 
 
MS. JACOBS: So we don't have tons of time left 
but do you have questions? Anybody have questions? 
 
UNIDENTIFIED SPEAKER: I missed whether or 
not you got that all unsealed or not. 
 
MR. MCGINLEY: Yes. 
 
MR. EYRE: Well, actually, companies that settled 
previously were allowed to keep their numbers under 
seal, who had settled previously with the State. But we 
got most of the larger companies. 
 
MR. MCGINLEY: The complaints in— the second 
amended complaint is in the materials and it does say 
redacted, that was almost wholly redacted, so we have 
some of the ones that settled. The judge let them off the 
hook. I think we could still get that through— 
 
MR. EYRE: Miami-Luken was the one— probably 
the one— the largest of the ones that were nonexempt. 
But a lot of them are real small and didn't have large 
distributions in the state. And I could see from the DEA 
data that I had later which ones were, you know, larger. 
We got Amerisource Bergen, we got Cardinal Health. The 
McKesson case is a separate lawsuit that's still pending. 
 
UNIDENTIFIED SPEAKER: Well, the same way 
that the states sue tobacco companies, is that going on 
yet? 
 
MR. EYRE: Yeah. And one thing we haven't 
talked about yet is that there's been some evidence, in 
particular with McKesson and Miami-Luken, that there 
were concerns brought to higher-ups, to executives, from 
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regional managers, and things like that, that these 
numbers were extraordinarily high. There was 
something with the McKesson, there's a separate action 
against McKesson by shareholders in Delaware and 
there's allegations that there were actually concerns 
brought by certain employees to the Board of Directors 
and they didn't do anything, allegations. 
 
MS. JACOBS: And, interestingly, one of the main 
tobacco lawyers, Mike Moore, is involved in a lot of these 
suits, the pharmaceutical suits, also on the plaintiff's 
side. So they're getting that same coalition together to 
work on these pharmaceutical cases. 
 
MR. MCGINLEY: One of the problems with those 
suits is if the plaintiffs are awarded compensation, will it 
go to deal with the problem. That's one of the problems 
with the tobacco suits and the lawyers— there's a lot of 
good lawyers. Moore is, you know, he's effective but— and 
they will make money. That’s what lawyers do. But will 
the proceeds go to help solve the problem. 
 
UNIDENTIFIED SPEAKER: I have some family 
there, married into family that's from Boone County. So 
I guess what I'm thinking is what now. There's all of this. 
Obviously your work has exposed a lot of this. But what 
is happening in West Virginia to try to help these people? 
 
MR. EYRE: They did take the money from the 
settlements and put it towards treatment beds but the 
sad thing is— 
 
UNIDENTIFIED SPEAKER: The trouble with 
those towns, like when I go to visit my husband's 
grandmother who is in Madison, you know, she's lived 
there— 
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MR. EYRE: That's where all this started, in 
Madison. 
 
UNIDENTIFIED SPEAKER: Yeah. 
 
MR. EYRE: Everything started in Madison. 
 
UNIDENTIFIED SPEAKER: Like I know where 
Larry's is, you know, I've driven past there. There's no 
one hardly left in the town, I mean, they've either moved 
away, died. 
 
MR. MCGINLEY: One of the problems is that, you 
know, people who are disempowered who have lost their 
jobs in the coal industry, you know, they've lived in the 
area, their family has been there for generations, what do 
you do. And, you know, coalminers that were injured, 
they take painkillers, and it just steamrolls. And an 
economy that is already going down is plagued by this 
epidemic. And it's an enormous problem. I would say— I 
mean, there are certainly well-meaning people 
throughout West Virginia who are trying to come up with 
solutions, but there's a lot of talk too and there are people 
who are trying to make a profit off of the solutions. 
 
UNIDENTIFIED SPEAKER: And not enough 
money, right— 
 
MR. MCGINLEY: Right. 
 
UNIDENTIFIED SPEAKER: —to actually help 
all the people that actually have problems? 
 
MR. MCGINLEY: Right. 
 
UNIDENTIFIED SPEAKER: So unless it's on a 
national level— 
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MR. EYRE: And the problem is it keeps shifting, 
you know, it went to heroin, and then it went to Fentanyl. 
And now— I was just a week-and-a-half ago in Madison 
talking to Judge Thompson— you probably knew Judge 
Thompson— he said now I'm seeing all this crystal meth 
and cocaine overdoses. So it keeps shifting when you— 
 
UNIDENTIFIED SPEAKER: What about the 
pharmacists and the doctors, any disciplinary action, 
anything happening to the people who— 
 
MR. MCGINLEY: A little. 
 
MR. EYRE: The pain clinic, they— but that was 
like three years too late— but they finally indicted 12 
doctors that were affiliated with The Hope Clinic for 
something that occurred back in 2012 to 2015. 
 
UNIDENTIFIED SPEAKER: I'm from Tyler 
County. I did my undergraduate at WVU. I just recently 
last summer spent the summer working with the drug 
court of the Circuit of Marshall, Tyler, and Wetzel, so I've 
seen first-hand the experience of the issue. Just kind of 
piggybacking off of her question, it seems like the 
Suboxone is becoming a replacement for the addiction. I 
just wondered if you had looked into or, you know, this 
could speak to that issue that we are replacing a drug 
dependency with another prescription that has a high 
risk of dependency. 
 
MR. EYRE: Well, the Boone County judge has his 
drug court too and he is very upset because he's directed 
to do the treatment with Suboxone and they are diverting 
the Suboxone. Another problem that's cropped up is 
many of these "pill mill" doctors that lost their licenses 
and went to jail, they are out of jail now and now they are 
opening up Suboxone clinics next to legitimate, you know, 
the more corporate Suboxone clinics. They're opening up 
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and they are not doing any counseling, they're not doing 
anything but just handing out the sublingual things that 
they take. 
 
MR. MCGINLEY: That's a really important 
question. I know that there is some discussion in the 
panels this afternoon. I know Suzanne Weise is here and 
she's going to talk about it from her experience with the 
Child & Family Law Clinic at WVU. I want to give 
Suzanne the shoutout too because she was co-counsel in 
the FOIA cases and in our intervention in the "pill mill" 
cases. But I think that's going to come up in discussion 
this afternoon. 
 
MS. JACOBS: That's another interesting legal 
consequence though. Suboxone's maker is a British 
company, Reckitt Benckiser, and they actually are being 
sued by 35 U.S. states for artificially inflating their prices 
and for fraudulently trying to delay their patent 
expiration so to prevent generics coming in. So the kind 
of collateral consequences, again, you know, they are 
making all this money off of the crisis and now you have 
to address their bad actions because they've got a product 
that everybody suddenly needs, so . . . 
 
MR. EYRE: Yeah. The drug money that they 
distributed, they did some new grants for treatment, 
Suboxone people have a very strong lobby down at the 
Legislature, so all faith-based, peer-to-peer type 
programs were excluded from funding because they got it 
written in that you had to do medication-assisted 
treatment in order to qualify for funding into the grants. 
You've probably seen that with the drug courts; right? 
 
UNIDENTIFIED SPEAKER: Yeah. 
 
MS. JACOBS: One more. I think we have time for 
one more. 
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[315] 
 
UNIDENTIFIED SPEAKER: Tell us what it's like 
the afternoon you get a telephone call and they tell you 
you've won the Pulitzer Prize. 
 
MR. EYRE: I was in shock for about three months. 
Yeah. We're— unlike the— we're just a little-bitty paper, 
30-some thousand in Charleston, West Virginia. I had 
always thought when you got the Pulitzer Prize that it 
was— if you've ever seen the photos in the New York 
Times and Washington Post, they're standing there with 
champagne bottles like they get tipped off. And then I 
realized later, they didn't really get tipped off but they 
just win one every year. Yeah, it was a bit crazy and . . . 
I don't know. The sad end of this, and I don't want to end 
on a sad note, but the numbers have continued to climb 
of the overdose deaths, as yours has as well. I think yours 
went up by I think 12 or 15 percent, again, because it's a 
moving target. But we at least have good people on the 
ground that are trying to work on it. 
 
MS. JACOBS: Thank you for the work you've 
done, and Suzanne. Thank you, guys. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31
et al.: Healing Appalachia: Keynote Address
Published by Trace: Tennessee Research and Creative Exchange, 2018
